Merck & Co.
MRK
$143.79
-0.73%
Merck & Co., Inc. is a global pharmaceutical powerhouse that develops and commercializes prescription medicines, vaccines, and animal health products across therapeutic areas including oncology, cardiometabolic disease, and infectious disease, with its immuno-oncology franchise led by Keytruda serving as the single largest contributor to overall sales. The company is best characterized as a large-cap, science-driven platform leader in the drug manufacturing industry, distinguished by the scale of its oncology and vaccine franchises (including Gardasil for HPV) and a growing animal health business, with roughly 53% of 2025 human health sales generated in the United States. The current investor narrative has been electrified by the historic Phase 3 success of an mRNA cancer vaccine developed in partnership with Moderna — the first such trial to succeed — which has reframed Merck as a potential long-term winner in next-generation oncology rather than merely a Keytruda-dependent cash cow. At the same time, debate persists around the company's aggressive acquisition spending (roughly $8.8 billion in Q1 2026 alone), a quarterly GAAP loss driven by large one-time charges, and the eventual patent cliff facing Keytruda, making this a story of pipeline reinvention balanced against near-term earnings noise.…
MRK
Merck & Co.
$143.79
Related headlines
Investment Opinion: Should I buy MRK Today?
Synthesized rating: Buy. The core thesis is that Merck offers a favorable risk/reward for patient investors: a 14.42x trailing PE and 3.10% dividend yield provide downside support, while the first successful Phase 3 mRNA cancer vaccine creates a credible long-term growth catalyst that the market has not fully priced. The analyst consensus of 'buy' (mean rating 1.75) with an average target of $152.96 (6.3% upside) and a high target of $186 (29.2% upside) anchors this view.
Supporting evidence includes: (1) revenue growth of 4.27% year-over-year in Q1 2026, stable but modest; (2) a 71.98% trailing gross margin and 36.17% operating margin, reflecting strong product-level economics; (3) TTM free cash flow of $14.115 billion, easily covering the $2.105 billion quarterly dividend and $874 million in buybacks; (4) a forward PE of 15.07x versus a large-cap pharma peer range of 15x–20x, suggesting a slight discount; and (5) a PEG ratio of 1.81, which is reasonable for a low-single-digit grower with pipeline optionality. The 34.70% ROE and 11.87% ROA further demonstrate efficient capital deployment.
The biggest risks that could invalidate this thesis are: (1) a faster-than-expected Keytruda patent cliff eroding the $14.349 billion pharmaceutical segment; (2) failure of the mRNA cancer vaccine to achieve commercial scale, which would remove the primary growth catalyst; and (3) continued acquisition spending ($8.779 billion in Q1 2026) straining the balance sheet and pressuring free cash flow. The rating would upgrade to a stronger Buy if the forward PE compresses below 13x or if mRNA vaccine revenue guidance exceeds $2 billion. It would downgrade to Hold if revenue growth decelerates below 3% or if Keytruda sales decline more than 10% year-over-year. Relative to its own history (PE range 9.04x–23.96x) and peers, MRK appears fairly valued with a modest upward bias, not overvalued.
Sign up to view all
MRK 12-Month Price Forecast
Merck presents a balanced risk/reward with a bullish tilt, supported by a modest valuation (14.42x trailing PE), strong cash generation ($14.115 billion TTM FCF), and a 3.10% dividend yield. The mRNA cancer vaccine Phase 3 success is a genuine game-changer that could offset the eventual Keytruda patent cliff, but commercial execution remains unproven. The stock's low beta of 0.226 and 69.03% one-year outperformance suggest it is a defensive momentum leader, though the 8.0% pullback from its August high indicates near-term consolidation. I would upgrade to high confidence if Q3 2026 revenue growth exceeds 5% and the mRNA vaccine receives FDA priority review; I would downgrade to neutral if Keytruda sales decline more than 5% year-over-year or if acquisition-related charges persist into Q2 2026.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Merck & Co.'s 12-month outlook, with a consensus price target around $152.96 and implied upside of +6.4% versus the current price.
Average Target
$152.96
0 analysts
Implied Upside
+6.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$105 - $186
Analyst target range
Merck is covered by 26 analysts with a consensus recommendation of "buy" (mean rating of 1.75 on a scale where 1 is Strong Buy), reflecting broad institutional confidence in the franchise. The average price target of $152.96 implies approximately 6.3% upside from the current price of $143.93, a modest but positive expected return that aligns with the stock's recent consolidation below its August highs. The consensus leans moderately bullish, though the relatively contained upside suggests much of the near-term good news — particularly the mRNA vaccine Phase 3 success — may already be reflected in the price.
The target range spans a wide $105.00 low to $186.00 high, a spread of $81 (roughly 56% of the current price), signaling meaningful disagreement among analysts about Merck's trajectory. The $186 high target likely assumes successful commercialization of the mRNA cancer vaccine, sustained Keytruda growth, and multiple expansion toward 18-20x forward earnings, while the $105 low target appears to price in Keytruda patent-cliff erosion, margin compression from acquisition integration, and a de-rating to low-double-digit multiples. Recent institutional ratings show a stable-to-constructive tone — BMO Capital, Guggenheim, JP Morgan, RBC Capital, Wells Fargo, B of A, and Scotiabank all maintain Outperform/Buy/Overweight ratings as of mid-2026, with Morgan Stanley and Cantor Fitzgerald holding Equal Weight/Neutral — indicating no recent downgrades but also a cadre of cautious voices. The estimated EPS average of $10.18 (range $9.91 to $10.53) and revenue estimate of $75.56 billion provide a solid earnings base, and the wide target dispersion argues for position sizing that respects the binary nature of pipeline outcomes.
Drowning in data?
Find the real signal!
Bulls vs Bears: MRK Investment Factors
The bull case currently holds stronger evidence, anchored by the historic mRNA cancer vaccine Phase 3 success, 69.03% one-year relative outperformance, and a 14.42x trailing PE that sits below the large-cap pharma peer band. However, the bear case is not without merit: low-single-digit revenue growth of 4.27%, a $4.24 billion Q1 2026 GAAP loss, and the looming Keytruda patent cliff create real uncertainty. The single most important tension is whether the mRNA vaccine platform can scale commercially fast enough to offset Keytruda's eventual revenue erosion — if it can, the stock's modest multiple leaves room for significant re-rating; if it cannot, the current price may already reflect overly optimistic pipeline assumptions. The market appears to be pricing a balanced outcome, with the average analyst target of $152.96 implying only 6.3% upside from $143.93.
Bullish
- mRNA Cancer Vaccine Breakthrough: The first-ever successful Phase 3 trial of an mRNA cancer vaccine, developed with Moderna, triggered a 12.6% single-day gap higher on August 19, 2026, from $135.17 to $152.20. This validates a next-generation oncology platform that could offset the eventual Keytruda patent cliff and opens a multi-billion-dollar revenue opportunity.
- Massive Relative Strength vs. Market: MRK is up 69.03% over the past year versus the S&P 500's 16.22%, with a 1-year relative strength of 52.81. Year-to-date, the stock has gained 35.21% against SPY's 12.08%, demonstrating persistent institutional accumulation and momentum leadership.
- Undemanding Valuation with Income Cushion: The trailing PE of 14.42x and forward PE of 15.07x sit in the lower-middle of Merck's historical range (9.04x–23.96x) and below the 15x–20x large-cap pharma peer band. A 3.10% dividend yield with a sustainable 44.79% payout ratio adds a meaningful income component.
- Fortress Cash Generation and Balance Sheet: TTM free cash flow of $14.115 billion comfortably covers the $2.105 billion quarterly dividend and $874 million in buybacks. The current ratio of 1.54 and debt-to-equity of 0.96 reflect an investment-grade balance sheet with ample liquidity.
Bearish
- Keytruda Patent Cliff Looms: Keytruda is the single largest contributor to Merck's pharmaceutical segment revenue of $14.349 billion in Q1 2026. The eventual loss of exclusivity represents a structural earnings risk that the market is pricing in via the modest 14.42x trailing PE.
- Q1 2026 GAAP Loss and Negative EBITDA: Merck reported a Q1 2026 net loss of $4.24 billion (EPS -$1.72) and negative EBITDA of -$2.022 billion, driven by $12.558 billion in R&D spending and $1.65 billion in other expenses. This earnings volatility complicates the near-term valuation picture.
- Aggressive Acquisition Spending Strains Cash: Merck deployed $8.779 billion on acquisitions in Q1 2026 alone, driving a net cash decrease of $9.292 billion and leaving $5.398 billion in cash. Sustaining this M&A pace alongside the dividend could pressure the balance sheet or require new debt.
- Slowing Top-Line Growth: Q1 2026 revenue grew just 4.27% year-over-year to $16.286 billion, continuing a low-single-digit trend (Q4 2025 grew 4.5%). This modest growth rate may not justify multiple expansion without a pipeline catalyst.
MRK Technical Analysis
Merck is in a powerful, sustained uptrend, with the shares up 69.03% over the past year and 35.21% year-to-date, dramatically outpacing the S&P 500's 16.22% and 12.08% respective gains. At a current price of $143.93, the stock sits at approximately 83.4% of its 52-week range (low of $77.58, high of $156.92), positioning it in the upper quartile of its annual band — a zone that typically signals institutional accumulation and momentum leadership, though it also raises the risk of profit-taking as the stock approaches its prior peak. The relative strength readings confirm this dominance, with a 1-year relative strength of 52.81 versus SPY, indicating Merck has nearly tripled the market's return over that window.
Short-term momentum remains firmly positive but is showing early signs of cooling: the stock is up 8.28% over the past month and 20.90% over three months, both well ahead of SPY's -1.06% and 3.04% respective moves, with 1-month relative strength of 9.34. The most striking feature of the chart is the mid-August gap higher, when the stock vaulted from $135.17 on August 18 to $152.20 on August 19 — a single-session gain of roughly 12.6% — almost certainly tied to the landmark mRNA cancer vaccine Phase 3 news. Since peaking at $156.45 on August 25, however, the stock has drifted lower to $143.93, a pullback of about 8.0% from that high, suggesting the initial news-driven surge is being digested and momentum is decelerating even as the longer-term trend remains intact.
Key technical support rests at the 52-week low of $77.58, though a more relevant near-term support zone lies around the pre-gap level of $135 and the August 19 breakout point near $152 now acting as resistance alongside the 52-week high of $156.92. A decisive breakout above $156.92 would confirm the uptrend's continuation and likely open the door to new all-time highs, while a breakdown below $135 would signal that the vaccine-driven gap is being fully retraced and could trigger a deeper mean-reversion toward the $120s. Notably, Merck's beta of just 0.226 means the stock is roughly 77% less volatile than the broader market, an unusually defensive profile for a momentum leader — this low beta supports smaller position-sizing adjustments for risk but also implies the recent sharp move was driven by idiosyncratic, stock-specific catalysts rather than market beta, and the maximum drawdown of -11.9% underscores a historically shallow risk profile.
Beta
0.23
0.23x market volatility
Max Drawdown
-11.9%
Largest decline past year
52-Week Range
$78-$157
Price range past year
Annual Return
+77.5%
Cumulative gain past year
| Period | MRK Return | S&P 500 |
|---|---|---|
| 1m | +5.9% | -2.4% |
| 3m | +24.6% | +2.2% |
| 6m | +25.9% | +14.8% |
| 1y | +77.5% | +14.6% |
| ytd | +35.1% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MRK Fundamental Analysis
Merck's revenue trajectory is stable but modestly growing, with Q1 2026 revenue of $16.286 billion representing 4.27% year-over-year growth versus Q1 2025's $15.619 billion, continuing a pattern of low-single-digit expansion (Q4 2025 revenue of $16.324 billion grew just 4.5% over Q4 2024's $15.624 billion). The segment mix shows the Pharmaceutical segment dominating at $14.349 billion, dwarfing Animal Health at $1.791 billion and Other at $0.146 billion, meaning the investment case rises and falls almost entirely on the pharma pipeline — particularly Keytruda and the newly validated mRNA cancer vaccine platform. While growth is not accelerating, the consistency of mid-single-digit top-line gains, combined with the optionality from a successful Phase 3 oncology vaccine, gives the story a favorable asymmetric skew.
Profitability presents a tale of two quarters: Q1 2026 reported a net loss of $4.24 billion with negative EPS of -$1.72 and negative EBITDA of -$2.022 billion, driven by $12.558 billion in R&D spending and $1.65 billion in other expenses, yet the trailing gross margin remains a robust 71.98% and the operating margin 36.17%. The prior quarter (Q4 2025) was solidly profitable with $2.963 billion in net income, a 18.15% net margin, and $6.297 billion in EBITDA, illustrating that the Q1 loss is an anomaly tied to charges rather than a deterioration in the underlying business — the TTM net margin of 28.12% confirms the core earnings engine is healthy. For a big pharma peer group where net margins typically range from the high-teens to low-30s, Merck's normalized profitability sits comfortably in the upper tier, and the 81.92% gross margin in Q1 (versus 70.49% in Q4 2025) shows product-level economics remain exceptionally strong.
Merck's balance sheet is investment-grade solid but carries meaningful leverage: debt-to-equity stands at 0.96, the current ratio is a comfortable 1.54, and TTM free cash flow is a substantial $14.115 billion, easily covering the $2.105 billion in quarterly dividends (payout ratio of 44.79%) and $874 million in buybacks. The company generated $3.918 billion in operating cash flow in Q1 2026 against $991 million in capex, but deployed $8.779 billion on acquisitions, driving a net cash decrease of $9.292 billion and leaving $5.398 billion in cash at quarter-end — a reminder that management is prioritizing pipeline replenishment over balance-sheet hoarding. With ROE of 34.70% and ROA of 11.87%, Merck demonstrates highly efficient capital deployment, and the 3.10% dividend yield provides a meaningful income cushion, though the elevated acquisition pace means investors should monitor whether FCF generation can sustain both the dividend and the M&A strategy without further debt build.
Quarterly Revenue
$16.3B
2026-03
Revenue YoY Growth
+4.3%
YoY Comparison
Gross Margin
81.9%
Latest Quarter
Free Cash Flow
$14.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MRK Overvalued?
Because Merck's trailing net income is positive on a TTM basis (net margin of 28.12%), the PE ratio is the appropriate primary metric, and the stock trades at a trailing PE of 14.42x against a forward PE of 15.07x — an unusual inversion where the forward multiple exceeds the trailing, implying the market expects near-term EPS to dip (consistent with the Q1 2026 loss and heavy R&D/acquisition spending) before re-accelerating. The forward PE of 15.07x on estimated EPS of $10.18 suggests investors are paying a modest multiple for a company with a 3.10% dividend yield and a PEG ratio of 1.81, which is reasonable but not screamingly cheap for a low-single-digit grower. The EV/EBITDA of 10.59x and price-to-sales of 4.06x round out a valuation profile that sits in the middle of the large-cap pharma range.
Relative to the drug manufacturing sector, where large-cap peers often trade between 15x and 20x forward earnings, Merck's 15.07x forward PE represents a slight discount to the upper end of the peer band, while its 4.06x PS ratio is moderate for a company with 71.98% gross margins and a dominant oncology franchise. The price-to-book of 5.01x is elevated in absolute terms but reflects the asset-light, high-ROIC nature of pharmaceutical manufacturing and Merck's 34.70% ROE, which justifies a premium to book. On balance, Merck appears to be trading at a modest discount to its quality and franchise strength would warrant, suggesting the market is pricing in Keytruda patent-cliff risk and acquisition integration uncertainty rather than fully crediting the mRNA vaccine optionality.
Historically, Merck's PE has ranged widely — from a trough of 9.04x in Q3 2025 to a peak of 23.96x in Q1 2023, with the current 14.42x sitting in the lower-middle portion of that multi-year band. The PS ratio tells a similar story: at 4.06x today versus a historical range that has stretched from roughly 12.19x (Q3 2025) to over 21x in 2024, the current multiple is near the low end of its own history, though this partly reflects the different revenue base and margin structure across periods. The PB ratio of 5.01x is also below its 2024 peaks above 7x, reinforcing the view that Merck is not priced for perfection — if the mRNA cancer vaccine platform delivers commercially, there is room for multiple expansion toward the mid-to-high teens on forward earnings.
PE
14.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 9x~32x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.6x
Enterprise Value Multiple
Investment Risk Disclosure
Merck's financial risk profile is dominated by the concentration of revenue in its pharmaceutical segment ($14.349 billion of $16.286 billion in Q1 2026) and, within that, the Keytruda franchise. The Q1 2026 GAAP loss of $4.24 billion and negative EBITDA of -$2.022 billion, driven by $12.558 billion in R&D and $1.65 billion in other charges, illustrate how quickly headline earnings can swing. While TTM free cash flow of $14.115 billion and a 71.98% gross margin provide a strong buffer, the $8.779 billion acquisition outlay in Q1 2026 reduced cash to $5.398 billion and pushed debt-to-equity to 0.96, leaving less room for error if pipeline returns disappoint. The 44.79% payout ratio on the 3.10% dividend yield is manageable but would come under pressure if earnings volatility persists.
Market and competitive risks center on valuation compression and pipeline competition. At a forward PE of 15.07x, MRK trades at a slight discount to the upper end of the 15x–20x large-cap pharma band, but the PEG ratio of 1.81 suggests the market is not paying for hyper-growth. The beta of 0.226 means the stock is roughly 77% less volatile than the broader market, so macro-driven selloffs are less of a threat than idiosyncratic pipeline news. However, competitors are advancing: BioNTech and Moderna are racing in mRNA oncology, and Summit Therapeutics' ivonescimab recently outperformed AstraZeneca's Imfinzi in a Phase III biliary tract cancer trial, signaling intensifying competition in immuno-oncology. Any negative regulatory or clinical readout for Merck's mRNA vaccine or Keytruda could trigger a sharp de-rating given the stock's 8.0% pullback from its August 25 high of $156.45.
The worst-case scenario would combine a Keytruda patent-cliff acceleration, disappointing mRNA vaccine commercialization, and a broader de-rating of large-cap pharma multiples. In that scenario, MRK could retrace to its 52-week low of $77.58, representing a decline of approximately 46.1% from the current price of $143.93. The analyst low target of $105 implies a more moderate downside of 27.0%, but the historical maximum drawdown of -11.9% understates tail risk given the binary nature of pipeline outcomes. A realistic adverse case might see the stock fall to the $105–$115 range (-20% to -27%) if Q3 2026 earnings miss and analysts downgrade on Keytruda erosion concerns, with a more severe drop toward $77.58 if the mRNA platform fails to deliver commercial traction within 12–18 months.
FAQ
The most severe risk is the Keytruda patent cliff, as the drug is the largest contributor to Merck's $14.349 billion pharmaceutical segment revenue. Second, the Q1 2026 GAAP loss of $4.24 billion and negative EBITDA of -$2.022 billion highlight earnings volatility from heavy R&D ($12.558 billion) and acquisition spending ($8.779 billion). Third, competitive pressure in immuno-oncology is intensifying, with rivals like Summit Therapeutics' ivonescimab outperforming AstraZeneca's Imfinzi in a Phase III trial. Fourth, the wide analyst target range of $105–$186 signals disagreement about the company's trajectory, and a failure of the mRNA vaccine to scale commercially could trigger a de-rating toward the $105 low target.
Our 12-month forecast assigns a 55% probability to a base case target range of $145–$160, assuming mid-single-digit revenue growth and successful mRNA vaccine progression. The bull case (25% probability) targets $170–$186 on robust vaccine uptake and multiple expansion, while the bear case (20% probability) targets $105–$120 on Keytruda erosion and pipeline setbacks. The most likely scenario is the base case, with the key assumption being that revenue growth remains in the 4–5% range and Keytruda sales are stable through 2027. The average analyst target of $152.96 aligns with our base case midpoint.
MRK appears fairly valued with a slight undervaluation bias. Its trailing PE of 14.42x and forward PE of 15.07x sit in the lower-middle of its historical range (9.04x–23.96x) and below the 15x–20x large-cap pharma peer band. The PEG ratio of 1.81 is reasonable for a low-single-digit grower, and the 4.06x price-to-sales ratio is moderate given 71.98% gross margins. The market is pricing in Keytruda patent-cliff risk and acquisition integration uncertainty, but not fully crediting the mRNA vaccine optionality. If the vaccine commercializes successfully, multiple expansion toward 18–20x forward earnings could drive the stock toward $186.
From a risk/reward perspective, MRK offers a favorable setup for patient investors. The stock trades at 14.42x trailing earnings with a 3.10% dividend yield, and analysts see 6.3% upside to the average target of $152.96, with a high target of $186 implying 29.2% upside. The biggest downside risk is the Keytruda patent cliff, which could pressure revenue after 2028, but the successful Phase 3 mRNA cancer vaccine provides a credible offset. The low beta of 0.226 means the stock is less volatile than the market, making it suitable for conservative portfolios. It is a good buy for long-term investors comfortable with pipeline binary risk, but less attractive for short-term traders seeking rapid gains.
MRK is best suited for long-term investment, with a suggested minimum holding period of 2–3 years. The stock's low beta of 0.226 and 3.10% dividend yield make it a defensive income play, while the mRNA cancer vaccine catalyst is a multi-year story that will take time to commercialize. Short-term trading is less attractive given the 8.0% pullback from the August high and the binary nature of pipeline news, which can cause sharp but unpredictable moves. The 44.79% payout ratio and $14.115 billion TTM free cash flow support dividend sustainability, reinforcing the long-term thesis. Investors should monitor quarterly earnings and FDA updates but avoid reacting to short-term volatility.
